MedPath

Dapsone

Generic Name
Dapsone
Brand Names
Aczone
Drug Type
Small Molecule
Chemical Formula
C12H12N2O2S
CAS Number
80-08-0
Unique Ingredient Identifier
8W5C518302
Background

A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of malaria. (From Martindale, The Extra Pharmacopoeia, 30th ed, p157-8)

Indication

For the treatment and management of leprosy and dermatitis herpetiformis.

Associated Conditions
Acne Vulgaris, Bullous Systemic Lupus Erythematosus, Bullous dermatitis herpetiformis, Hansen's Disease, Pemphigus Vulgaris (PV), Relapsing Polychondritis, Mild Pneumocystis pneumonia, Mild Toxoplasma gondii encephalitis, Moderate Pneumocystis pneumonia, Moderate Toxoplasma gondii encephalitis, Refractory Idiopathic thrombocytopenic purpura
Clinical Trials
Related News

Efficacy and Safety of Aczone 7.5% Gel in the Treatment of Truncal Acne Vulgaris

Phase 4
Completed
Conditions
Acne
Interventions
First Posted Date
2016-10-25
Last Posted Date
2019-04-03
Lead Sponsor
Derm Research, PLLC
Target Recruit Count
20
Registration Number
NCT02944461
Locations
🇺🇸

Dermatology and Laser Surgery, Sacramento, California, United States

🇺🇸

James Q. DelRosso DO, LLC, Las Vegas, Nevada, United States

🇺🇸

DermResearch, PLLC, Louisville, Kentucky, United States

A Randomized Multicenter Study for Isolated Skin Vasculitis

Phase 2
Recruiting
Conditions
Primary Cutaneous Vasculitis
Cutaneous Polyarteritis Nodosa
IgA Vasculitis
Henoch-Schönlein Purpura
Interventions
First Posted Date
2016-10-20
Last Posted Date
2025-02-07
Lead Sponsor
University of Pennsylvania
Target Recruit Count
90
Registration Number
NCT02939573
Locations
🇺🇸

University of Pennsylvania, Philadelphia, Pennsylvania, United States

🇺🇸

Boston University School of Medicine, Boston, Massachusetts, United States

🇺🇸

Penn State Hershey Medical Center, Hershey, Pennsylvania, United States

and more 13 locations

Study Comparing Test to Aczone 5% and Both to a Placebo Control in the Treatment of Acne Vulgaris

Phase 1
Completed
Conditions
Acne Vulgaris
Interventions
Drug: Test.
Drug: Placebo
First Posted Date
2016-10-11
Last Posted Date
2017-05-04
Lead Sponsor
Taro Pharmaceuticals USA
Target Recruit Count
1134
Registration Number
NCT02929719

Trial of Dapsone 5.0% Gel in the Treatment of Acne Vulgaris

Phase 3
Completed
Conditions
Acne Vulgaris
Interventions
Other: Placebo
First Posted Date
2016-08-12
Last Posted Date
2016-12-20
Lead Sponsor
Seegpharm S.A.
Target Recruit Count
2361
Registration Number
NCT02865005
Locations
🇧🇿

Catawba Clinical Research, Belize City, Belize

Efficacy and Safety of DAPSone as a Second-line Option in Adult Immune Thrombocytopenia

First Posted Date
2015-12-11
Last Posted Date
2017-07-26
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
216
Registration Number
NCT02627417
Locations
🇫🇷

Henri Mondor Hospital, Creteil, France

Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome

Phase 4
Conditions
Allergic Cutaneous Vasculitis
Urticaria
Psoriasis
Sterile Pustulosis
Leprosy
Acne
Pneumocystis Pneumonia
Bullous Skin Diseases
Interventions
Genetic: HLA-B*1301
First Posted Date
2015-09-15
Last Posted Date
2017-03-03
Lead Sponsor
Shandong Provincial Institute of Dermatology and Venereology
Target Recruit Count
3130
Registration Number
NCT02550080
Locations
🇨🇳

Shandong Provincial Institute of Dermatology and Venereology, Jinan, Shandong, China

Pharmacokinetics and Distribution of Dapsone in Leucocytes After Single-dose and Multiple-dose Administration

Phase 1
Completed
Conditions
Methemoglobinemia
Linear IgA Bullous Dermatosis
Interventions
Biological: leucocytes
Biological: Met-Hb
First Posted Date
2015-07-09
Last Posted Date
2015-07-09
Lead Sponsor
University Medicine Greifswald
Target Recruit Count
23
Registration Number
NCT02493283
Locations
🇩🇪

Department of Clinical Pharmacology, Ernst-Moritz-Arndt-University Greifswald, Greifswald, Mecklenburg-Vorpommern, Germany

Photoallergy Potential of Dapsone Gel in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
First Posted Date
2014-04-21
Last Posted Date
2018-10-09
Lead Sponsor
Almirall, S.A.
Target Recruit Count
58
Registration Number
NCT02117739

Dermal Tolerability of Dapsone Gel in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Normal saline
First Posted Date
2014-04-21
Last Posted Date
2018-10-09
Lead Sponsor
Almirall, S.A.
Target Recruit Count
237
Registration Number
NCT02117752

Phototoxicity Test of Dapsone Gel in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
First Posted Date
2014-04-09
Last Posted Date
2018-10-09
Lead Sponsor
Almirall, S.A.
Target Recruit Count
33
Registration Number
NCT02108483
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy